Top

Published in:

01-05-2018 | Laboratory Investigation

Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis

Authors: Akio Kimura, Masao Takemura, Ginette Serrero, Nobuaki Yoshikura, Yuichi Hayashi, Kuniaki Saito, Takashi Inuzuka

Published in: Journal of Neuro-Oncology | Issue 3/2018

Abstract

Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS⁺); 6 without CNS metastasis (CNS⁻)], 21 with carcinomas (10 CNS⁺; 11 CNS⁻), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS⁺ lymphoma group were significantly higher than in the CNS⁻ lymphoma and control non-cancer groups; and were also significantly higher in the CNS⁺ carcinoma group than in the CNS⁻ carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS⁺ lymphoma from CNS⁻ lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS⁺ carcinomas from CNS⁻ carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS⁺ lymphoma and carcinomas compared to corresponding CNS⁻ diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS⁺ lymphoma and metastasis.

Available only for authorised users

Lee W, Kim SJ, Lee S et al (2005) Significance of cerebrospinal fluid sIL-2R level as a marker of CNS involvement in acute lymphoblastic leukemia. Ann Clin Lab Sci 35:407–412PubMed

Hansen PB, Kjeldsen L, Dalhoff K, Olesen B (1992) Cerebrospinal fluid beta-2-microglobulin in adult patients with acute leukemia or lymphoma: a useful marker in early diagnosis and monitoring of CNS-involvement. Acta Neurol Scand 85:224–227CrossRefPubMed

Aviles A, Gómez R, Salas J (1991) Ferritin in the cerebrospinal fluid as an early indicator of neuromeningeal involvement in patients with malignant lymphoma. Gac Med Mex 127:249–252 (Spanish)PubMed

Roy S, Josephson SA, Fridlyand J et al (2008) Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 26:96–105CrossRefPubMed

Baraniskin A, Kuhnhenn J, Schlegel U et al (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117:3140–3146CrossRefPubMed

Wei D, Wan Q, Li L et al (2015) MicroRNAs as potential biomarkers for diagnosing cancers of central nervous system: a meta-analysis. Mol Neurobiol 51:1452–1461CrossRefPubMed

Yu X, Li Z, Shen J, Chan MT, Wu WK (2016) Role of microRNAs in primary central nervous system lymphomas. Cell Prolif 49:147–153CrossRefPubMed

Viaccoz A, Ducray F, Tholance Y et al (2015) CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro Oncol 17:1497–1503CrossRefPubMedPubMedCentral

Strehlow F, Bauer S, Martus P et al (2016) Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. J Neurooncol 129:165–171CrossRefPubMed

10.

Rubenstein JL, Wong VS, Kadoch C et al (2013) CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 121:4740–4748CrossRefPubMedPubMedCentral

11.

Fischer L, Korfel A, Pfeiffer S et al (2009) CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res 15:5968–5973CrossRefPubMed

12.

Berghoff AS, Stefanits H, Woehrer A et al (2013) Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clin Neuropathol 32:148–158CrossRefPubMedPubMedCentral

13.

Ahluwalia MS, Wallace PK, Peereboom DM (2012) Flow cytometry as a diagnostic tool in lymphomatous or leukemic meningitis: ready for prime time? Cancer 118:1747–1753CrossRefPubMed

14.

He Z, Bateman A (1999) Progranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo. Cancer Res 59:3222–3229PubMed

15.

He Z, Ismail A, Kriazhev L, Sadvakassova G, Bateman A (2002) Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res 62:5590–5596PubMed

16.

He Z, Bateman A (2003) Progranulin (granulin–epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 81:600–612CrossRefPubMed

17.

Serrero G (2003) Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis. Biochem Biophys Res Commun 308:409–413CrossRefPubMed

18.

Ong CH, Bateman A (2003) Progranulin (granulin–epithelin precursor, PC-cell derived growth factor, acrogranin) in proliferation and tumorigenesis. Histol Histopathol 18:1275–1288PubMed

19.

Serrero G, Ioffe OB (2003) Expression of PC-cell-derived growth factor in benign and malignant human breast epithelium. Hum Pathol 34:1148–1154CrossRefPubMed

20.

Ho JC, Ip YC, Cheung ST et al (2008) Granulin–epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 47:1524–1532CrossRefPubMed

21.

Cuevas-Antonio R, Cancino C, Arechavaleta-Velasco F et al (2010) Expression of progranulin (acrogranin/PCDGF/granulin–epithelin precursor) in benign and malignant ovarian tumors and activation of MAPK signaling in ovarian cancer cell line. Cancer Invest 28:452–458CrossRefPubMed

22.

Dong T, Yang D, Li R et al (2016) PGRN promotes migration and invasion of epithelial ovarian cancer cells through an epithelial mesenchymal transition program and the activation of cancer associated fibroblasts. Exp Mol Pathol 100:17–25CrossRefPubMed

23.

Tangkeangsirisin W, Hayashi J, Serrero G (2004) PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res 64:1737–1743CrossRefPubMed

24.

Tangkeangsirisin W, Serrero G (2004) PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis 25:1587–1592CrossRefPubMed

25.

Matsumura N, Mandai M, Miyanishi M et al (2006) Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in vivo tumorigenesis. Clin Cancer Res 12:1402–1411CrossRefPubMed

26.

Frampton G, Invernizzi P, Bernuzzi F et al (2012) Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 61:268–277CrossRefPubMed

27.

Frampton G, Ueno Y, Quinn M et al (2012) The novel growth factor, progranulin, stimulates mouse cholangiocyte proliferation via sirtuin-1-mediated inactivation of FOXO1. Am J Physiol Gastrointest Liver Physiol 303:G1202–G1211CrossRefPubMedPubMedCentral

28.

Göbel M, Eisele L, Möllmann M et al (2013) Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. PLoS ONE 8:e72107CrossRefPubMedPubMedCentral

29.

Edelman MJ, Feliciano J, Yue B et al (2014) GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma. Hum Pathol 45:1893–1899CrossRefPubMedPubMedCentral

30.

Monami G, Gonzalez EM, Hellman M et al (2006) Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res 66:7103–7110CrossRefPubMed

31.

Wang M, Li G, Yin J, Lin T, Zhang J (2012) Progranulin overexpression predicts overall survival in patients with glioblastoma. Med Oncol 29:2423–2431CrossRefPubMed

32.

Lu Y, Zheng L, Zhang W et al (2014) Growth factor progranulin contributes to cervical cancer cell proliferation and transformation in vivo and in vitro. Gynecol Oncol 134:364–371CrossRefPubMed

33.

Wei Z, Huang Y, Xie N, Ma Q (2015) Elevated expression of secreted autocrine growth factor progranulin increases cervical cancer growth. Cell Biochem Biophys 71:189–193CrossRefPubMed

34.

Demorrow S (2013) Progranulin: a novel regulator of gastrointestinal cancer progression. Transl Gastrointest Cancer 2:145–151PubMedPubMedCentral

35.

Yang D, Wang LL, Dong TT et al (2015) Progranulin promotes colorectal cancer proliferation and angiogenesis through TNFR2/Akt and ERK signaling pathways. Am J Cancer Res 5:3085–3097PubMedPubMedCentral

36.

Koo DH, Park CY, Lee ES, Ro J, Oh SW (2012) Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study. PLoS ONE 7:e39880CrossRefPubMedPubMedCentral

37.

Han JJ, Yu M, Houston N, Steinberg SM, Kohn EC (2011) Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol Oncol 120:5–10CrossRefPubMed

38.

Baker M, Mackenzie IR, Pickering-Brown SM et al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919CrossRefPubMed

39.

Cruts M, Gijselinck I, van der Zee J et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924CrossRefPubMed

40.

Van Damme P, Van Hoecke A, Lambrechts D et al (2008) Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181:37–41CrossRefPubMedPubMedCentral

41.

Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G (2008) Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71:1235–1239CrossRefPubMed

42.

Tkaczuk KR, Yue B, Zhan M et al (2011) Increased circulating level of the survival factor GP88 (Progranulin) in the serum of breast cancer patients when compared to healthy subjects. Breast Cancer (Auckl) 5:155–162

43.

Yamamoto Y, Takemura M, Serrero G et al (2014) Increased serum GP88 (progranulin) concentrations in rheumatoid arthritis. Inflammation 37:1806–1813CrossRefPubMed

Title: Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis
Authors: Akio Kimura
Masao Takemura
Ginette Serrero
Nobuaki Yoshikura
Yuichi Hayashi
Kuniaki Saito
Takashi Inuzuka
Publication date: 01-05-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2742-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Increasing FLAIR signal intensity in the postoperative cavity predicts progression in gross-total resected high-grade gliomas

Neurologic complications of immune checkpoint inhibitors

Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma

Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas

Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules